Literature DB >> 16146276

Liposarcoma of the spermatic-cord: description of two clinical cases and review of the literature.

Michele Malizia1, Eugenio Brunocilla, Alessandro Bertaccini, Fabiano Palmieri, Giovanni Vitullo, Giuseppe Martorana.   

Abstract

Spermatic cord liposarcoma is a rare tumor; currently only 161 cases are described in literature. Natural history of these tumors is marked by the high local recurrence rate. Radical surgery represents the therapy of choice whilst uncertain is the role of regional and retroperitoneal lymphadenectomy as well as the usefulness of adjuvant radiotherapy or chemotherapy. In this paper we describe our experience of two cases treated at our Department between 1995 and 2002 and discuss about the clinical management of this misleading tumor in the light of the several experiences reported in literature.

Entities:  

Mesh:

Year:  2005        PMID: 16146276

Source DB:  PubMed          Journal:  Arch Ital Urol Androl        ISSN: 1124-3562


  4 in total

1.  Current management of liposarcoma of the spermatic cord: A case report and review of the literature.

Authors:  Charbel Chalouhy; Jessica M Ruck; Maroun Moukarzel; Roy Jourdi; Nabil Dagher; Benjamin Philosophe
Journal:  Mol Clin Oncol       Date:  2017-02-06

2.  Well differentiated liposarcoma of spermatic cord: report of 3 rare cases.

Authors:  Maryam Abolhasani; Mashaallah Babashahi; Tina Shooshtarizadeh; Mojgan Asgari; Hossein Shahrokh; Pejman Shadpour; Maryam Emami
Journal:  Med J Islam Repub Iran       Date:  2014-02-22

Review 3.  Liposarcoma of the spermatic cord mimicking a left inguinal hernia: a case report and literature review.

Authors:  Fubiao Li; Runhui Tian; Changjiu Yin; Xiaofan Dai; Hongliang Wang; Ning Xu; Kaimin Guo
Journal:  World J Surg Oncol       Date:  2013-01-25       Impact factor: 2.754

Review 4.  Recurrence of paratesticular liposarcoma: a case report and review of the literature.

Authors:  Raimondo Gabriele; Giuseppe Ferrara; Maria Rita Tarallo; Alessio Giordano; Antonietta De Gori; Luciano Izzo; Marco Conte
Journal:  World J Surg Oncol       Date:  2014-08-29       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.